Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Combined with Blinatumomab in High-Relapse-Risk Pediatric B-ALL
ChiCTR2400083604Phase 4Not yet recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoint: minimal residual disease. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2400083604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083604.